JTCS Click here to go to SJM website.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Marcio Scorsin
Nawwar Al Attar
Richard Raffoul
Patrick Nataf
Arrigo Lessana
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scorsin, M.
Right arrow Articles by Lessana, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scorsin, M.
Right arrow Articles by Lessana, A.
Related Collections
Right arrow Myocardial protection

J Thorac Cardiovasc Surg 2003;125:1022-1029
© 2003 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Efficacy of esmolol as a myocardial protective agent during continuous retrograde blood cardioplegia

Marcio Scorsin, MD, PhD, Alexandre Mebazaa, MD, PhD, Nawwar Al Attar, FRCS, Betta Medini, MD, Jacques Callebert, PhD, Richard Raffoul, MD, Ramzi Ramadan, MD, Jean Michel Maillet, MD, Alain Ruffenach, MD, François Simoneau, MD, Patrick Nataf, MD, Didier Payen, MD, PhD, Arrigo Lessana, MD

From the Service de Chirurgie Cardiaque, Centre Cardiologique du Nord, Saint-Denis, France; Département d'Anesthésie-Réanimation, Service de Biochimie et de Biologie Moléculaire, CR Claude Bernard "Pathologie Expérimentale et Communications Cellulaires," Institut Fédératif de Recherche, Hôpital Lariboisière, Paris, France.

Read at the Eighty-second Annual Meeting of The American Association for Thoracic Surgery, Washington, DC, May 5-8, 2002.

Received for publication May 29, 2002. Revisions requested July 8, 2002; revisions received July 22, 2002. Accepted for publication Aug 14, 2002. Address for reprints: Alexandre Mebazaa, MD, PhD (E-mail: mscorsin{at}hotmail.com), Département d'Anesthésie-Réanimation-SMUR, Hôpital Lariboisière, 2 rue Ambroise-Paré, 75475 Paris Cedex 10, France.

Objective: Esmolol, an ultra-short-acting ß-blocker, is known to attenuate myocardial ischemia-reperfusion injury. The aim of this study was to compare the effects of esmolol and potassium on myocardial metabolism during continuous normothermic retrograde blood cardioplegia.
Methods: Forty-one patients operated on for isolated aortic valve stenosis were randomly assigned to continuous coronary infusion with either potassium or esmolol during cardiopulmonary bypass. Myocardial metabolism was assessed by measuring the transmyocardial gradient of oxygen content indexed to left ventricular mass of glucose, lactate, and nitric oxide. To do so, blood samples were simultaneously withdrawn upstream (in the cardioplegia line) and downstream of the myocardium (in the left coronary ostium) 10 and 30 minutes after aortic crossclamping.
Results: Although the cardioplegia flow rate and pressure were similar, esmolol markedly reduced the transmyocardial gradient of oxygen content indexed to left ventricular mass compared with potassium: 13 ± 6 vs 20 ± 6 mL of oxygen per liter of blood per 100 g of myocardium, respectively, at 10 minutes and 16 ± 8 vs 24 ± 8 mL of oxygen per liter of blood per 100 g of myocardium, respectively, at 30 minutes (P = .009). Coronary glucose and lactate transmyocardial gradients were similar in both groups, indicating adequate myocardial perfusion in all patients at all times. In addition, during retrograde cardioplegia, esmolol showed a lower nitric oxide release compared with that caused by potassium (39 ± 49 µmol x L-1 for potassium vs 14 ± 8 µmol x L-1 for esmolol at 10 minutes and 39 ± 47 µmol x L-1 for potassium vs 6 ± 8 µmol x L-1 for esmolol at 30 minutes, P = .05). However, hemodynamic parameters and plasma troponin I levels remained unchanged postoperatively between the 2 types of cardioplegia.
Conclusion: Esmolol provides potent myocardial protection in hypertrophied hearts, at least in part, by reducing myocardial oxygen metabolism.




This article has been cited by other articles:


Home page
 Eur. J. Cardiothorac. Surg.Home page
T. Fannelop, G. O. Dahle, K. Matre, C. A. Moen, A. Mongstad, F. Eliassen, L. Segadal, and K. Grong
Esmolol before 80 min of cardiac arrest with oxygenated cold blood cardioplegia alleviates systolic dysfunction. An experimental study in pigs
Eur. J. Cardiothorac. Surg., January 1, 2008; 33(1): 9 - 17.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The American Association for Thoracic Surgery.